Cargando…

A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study

BACKGROUND: Staphylococcus aureus bacteremia is a common infection associated with significant morbidity and mortality. Telavancin is a bactericidal lipoglycopeptide active against Gram-positive pathogens, including methicillin-resistant S. aureus (MRSA). We conducted a randomized, double-blind, Pha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stryjewski, Martin E, Lentnek, Arnold, O’Riordan, William, Pullman, John, Tambyah, Paul Anantharajah, Miró, Jose M, Fowler Jr, Vance G, Barriere, Steven L, Kitt, Michael M, Corey, G Ralph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048626/ https://www.ncbi.nlm.nih.gov/pubmed/24884578 http://dx.doi.org/10.1186/1471-2334-14-289

Ejemplares similares

Efficacy of telavancin for treatment of surgical site infections
por: Wilson, SE, et al.
Publicado: (2008)

Potential Role for Telavancin in Bacteremic Infections Due to Gram-Positive Pathogens: Focus on Staphylococcus aureus
por: Corey, G. Ralph, et al.
Publicado: (2015)

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens
por: Rubinstein, Ethan, et al.
Publicado: (2011)

Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure
por: Torres, A., et al.
Publicado: (2014)

Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia
por: Rubinstein, Ethan, et al.
Publicado: (2014)

Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates
por: Smart, Jennifer I., et al.
Publicado: (2016)

A Narrative Review of Early Oral Stepdown Therapy for the Treatment of Uncomplicated Staphylococcus aureus Bacteremia: Yay or Nay?
por: Dagher, Michael, et al.
Publicado: (2020)

Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies
por: Wilson, Samuel E., et al.
Publicado: (2017)

Bacteremic nosocomial pneumonia cases from the ATTAIN studies
por: Rubinstein, E, et al.
Publicado: (2010)

Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Reilly, Joseph, et al.
Publicado: (2020)

Echocardiography Is Dispensable in Uncomplicated Staphylococcus aureus Bacteremia
por: Khatib, Riad, et al.
Publicado: (2013)

Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011–2014)
por: Mendes, R. E., et al.
Publicado: (2017)

Telavancin for the treatment of hospital-acquired pneumonia in severely ill and older patients: the ATTAIN studies
por: Rubinstein, E, et al.
Publicado: (2009)

Top Questions in Uncomplicated, Non–Staphylococcus aureus Bacteremia
por: Sutton, Jesse D, et al.
Publicado: (2018)

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
por: Worboys, Philip D., et al.
Publicado: (2015)

Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials
por: Niederman, Michael S., et al.
Publicado: (2019)

Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia: Host, Pathogen, and Treatment
por: Parsons, Joshua B., et al.
Publicado: (2023)

Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)
por: Hooper, Candace Y, et al.
Publicado: (2012)

Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies
por: Barriere, Steven L, et al.
Publicado: (2014)

Uncomplicated Staphylococcus aureus Bacteremia Treatment Duration and Outcomes at an Academic Medical Center
por: Taupin, Daniel, et al.
Publicado: (2020)

Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Bressler, Adam M., et al.
Publicado: (2019)

1060. Risk Factors for Recurrent Staphylococcus aureus Bacteremia
por: Choi, Seong-Ho, et al.
Publicado: (2018)

Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial
por: Hamed, Kamal, et al.
Publicado: (2020)

Telavancin: A novel lipoglycopeptide antibiotic
por: Damodaran, S. E., et al.
Publicado: (2011)

Chemical Stability of Telavancin in Elastomeric Pumps()
por: Sand, Patrick, et al.
Publicado: (2015)

Genetic Variability in Beta-Defensins Is Not Associated with Susceptibility to Staphylococcus aureus Bacteremia
por: Fode, Peder, et al.
Publicado: (2012)

181. Demographic and Geographic Epidemiology of Staphylococcus aureus Bacteremia using Geographic Information Systems Mapping and Spatial Statistics
por: Marshall, Julia, et al.
Publicado: (2021)

Reply to Tarchini
por: Rubinstein, Ethan, et al.
Publicado: (2011)

Clinical Experience with Telavancin for the Treatment of Patients with Bone and Joint Infections: Preliminary Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles, et al.
Publicado: (2017)

1058. Prognostic Biomarkers for Persistent Bacteremia and Mortality in Complicated S. aureus Bloodstream Infection
por: Cao, Yi, et al.
Publicado: (2018)

Prognostic Power of Pathogen Cell-Free DNA in Staphylococcus aureus Bacteremia
por: Guimaraes, Alessander O, et al.
Publicado: (2019)

Global Differences in the Management of Staphylococcus aureus Bacteremia: No International Standard of Care
por: Westgeest, Annette C, et al.
Publicado: (2023)

Real-World Clinical Use and Outcomes of Telavancin for the Treatment of Bone and Joint Infections: Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles R., et al.
Publicado: (2021)

307. Exploring HLA genotypes as contributing risk factors in Staphylococcus aureus bacteremia
por: Tao, Yazhong, et al.
Publicado: (2023)

1373. Racial Disparities in Clinical Characteristics and Outcomes for Methicillin Susceptible and Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Mohnasky, Michael C, et al.
Publicado: (2021)

216. Bacterial Genotype and Clinical Outcomes in Solid Organ Transplant Recipients with Staphylococcus aureus Bacteremia
por: Eichenberger, Emily, et al.
Publicado: (2021)

Role of telavancin in treatment of skin and skin structure infections
por: Bonkowski, Joseph, et al.
Publicado: (2010)

Update on the emerging role of telavancin in hospital-acquired infections
por: Nnedu, Obinna N, et al.
Publicado: (2015)

Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides
por: al Jalali, Valentin, et al.
Publicado: (2018)

2364. Evaluation of Renal Function Changes in Patients With Prolonged Telavancin Therapy (>21 Days): Results From the Telavancin Observational Use Registry (TOUR™)
por: Hassoun, Ali, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ru9i339dlgflhq0252jefr40vj